Fluoxetine: A review of its therapeutic potential in the treatment of depression associated with physical illness

Drugs

Volumn 61, Issue 1, 2001, Pages 81-110

  Cheer, S M ^a   Goa, K L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DESIPRAMINE; FLUOXETINE; GLUCOSE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DRUG ABSORPTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FOOD INTAKE; GLUCOSE TOLERANCE; HUMAN; REVIEW; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SUICIDAL BEHAVIOR; WEIGHT REDUCTION;

EID: 0035132212     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161010-00010     Document Type: Review

References (161)

1. Management of depression in patients with coexisting medical illness
2. Changes in depressive symptoms as AIDS develops
3. Depression in the context of human immunodeficiency virus infection: Implications for treatment
4. Treatment of depression in HIV infection
5. Treatment of depression in HIV+ men: Literature review and report of an ongoing study of testosterone replacement therapy
6. Psychopharmacothy in the HIV-infected patient
7. Psychopharmacology in HIV-positive patients: Research perspectives
8. Prevalence of psychiatric disorders in HIV illness
9. Treatment of depression in patients with diabetes mellitus
10. Depression in adults with diabetes
11. Symptoms of depression in patients with type II diabetes mellitus
12. Memory self-assessment and performance in aged diabetics and nondiabetics
13. Cognitive and affective disorders in elderly diabetics
14. Affective disorders and cerebral vascular disease
15. Post-stroke depressive disorders: A follow-up study of 103 patients
16. Mood disorders in stroke patients: Importance of location of lesion
17. Comparison of cortical and subcortical lesions in the production of poststroke mood disorders
18. Depression and the cancer patient
19. Depression in breast cancer patients: The need for treatment
20. Depression in the medically ill: Choosing an antidepressant
21. Expanding psychopharmacologic treatment options for the depressed medical patient
22. Effects of dextroamphetamine on depression and fatigue in men with HIV: A double-blind, placebo-controlled trial
23. Fluoxetine treatment for depression in patients with HIV and AIDS: A randomized, placebo-controlled trial
24. Fluoxetine: A review of its use in anxiety and mixed anxiety and depression
25. Fluoxetine: A review of receptor and functional effects and their clinical implications
26. Fluoxetine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness
27. Fluoxetine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in older patients with depressive illness
28. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs)
29. In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment
30. How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRIs
31. Effect of fluoxetine on food intake of humans living in a residential laboratory
32. Fluoxetine in the treatment of obese Type 2 diabetic patients
33. Fluoxetine increases resting energy expenditure and basal body temperature in humans
34. The behavioural toxicity of the selective serotonin reuptake inhibitors
35. A comparative study of acute and subchronic effects of dothiepin, fluoxetine and placebo on psychomotor and actual driving performance
36. Comparative behavioural toxicity of the selective serotonin reuptake inhibitors
37. Effect of clinical doses of fluoxetine on psychological variables in healthy volunteers
38. Effects of serotonin reuptake inhibitors on haemostasis
39. Fluoxetine and hemostatic function: A pilot study
40. Study of haemostasis in depressive patients treated with fluoxetine
41. Clomipramine, fluoxetine, and glucose control
42. Hypoglycemia associated with the use of fluoxetine
43. Fluoxetine and blood glucose control in adolescents with major depression and insulin-dependent diabetes mellitus
44. Fluoxetine increases insulin action in obese nondiabetic and in obese non-insulin-dependent diabetic individuals
45. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss
46. Glucose clamp technique: A method for quantifying insulin secretion and resistance
47. Depressive effect and survival among gay and bisexual men infected with HIV
48. Depression, the immune system, and health and illness: Findings in search of meaning
49. Depression, distress, lymphocyte subsets, and human immunodeficiency virus symptoms on two occasions in HIV-positive homosexual men
50. Effects of fluoxetine on mood and immune status in depressed patients with HIV illness
51. Choosing appropriate antidepressant therapy in the elderly. A risk-benefit assessment of available agents
52. Fluoxetine treatment compromises the antiemetic efficacy of ondansetron in cancer patients
53. Pharmacokinetics of selective serotonin reuptake inhibitors: Clinical relevance
54. Clinical pharmacokinetics of fluoxetine
55. Pharmacokinetics of second generation antidepressants: Fluoxetine
56. Targeted pharmacotherapy in depression management: Comparative pharmacokinetics of fluoxetine, paroxetine and sertraline
57. Fluoxetine: Clinical pharmacology and physiologic disposition
58. Fluoxetine: An overview of its pharmacodynamic and pharmacokinetic properties and review of its therapeutic efficacy in obsessive-compulsive disorder
59. Human cytochromes mediating n-demethylation of fluoxetine in vitro
60. Identification of cytochrome P450 isoforms involved in fluoxetine N-demethylation by C-DNA expressed enzymes
61. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin
62. Translational pharmacokinetics: Current issues with newer antidepressants
63. Fluoxetine disposition and elimination in cirrhosis
64. Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function
65. Excretion of fluoxetine and its metabolite, norfluoxetine, in human breast milk
66. The pharmacokinetics of fluoxetine in elderly subjects
67. Fluoxetine: Age and dose dependent pharmacokinetics and CYP 2C19 inhibition
68. Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers
69. Drug interactions of clinical significance with selective serotonin reuptake inhibitors
70. Antidepressant drug interactions and the cytochrome P450 system: A critical appraisal
71. Outpatient managment of depression: A guide for the practitioner. 2nd edition
72. Antidepressants
73. Drug interactions of clinical importance: An updated guide
74. Drug interactions of HIV protease inhibitors
75. Effect of fluoxetine on pharmacokinetics of ritonavir
76. Ritonavir-fluoxetine interaction
77. Treatment of major depression in HIV-seropositive men
78. Structured group therapy and fluoxetine to treat depression in HIV-positive persons
79. Double-blind comparison of fluoxetine and desipramine in the treatment of depressed women with advanced HIV disease: A pilot study
80. Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection and AIDS. Improvements in affective and somatic symptoms
81. The efficacy of selective serotonin reuptake inhibitors (SSRIs) for the treatment of depression in patients with symptomatic HIV infection
82. Fluoxetine for depression in diabetes
83. Fluoxetine in early postroke depression: A double-blind placebo-controlled study
84. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: A placebo controlled, double-blind study
85. Effects of antidepressants on functional recovery following stroke: A double-blind study
86. Effects of early treatment of poststroke depression on neuropscyhological rehabilitation
87. The effect of fluoxetine on anxiety and depression symptoms in cancer patients
88. A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer
89. Fluoxetine treatment of depressed patients with HIV infection
90. A report of eight HIV-seropositive patients with major depression responding to fluoxetine
91. Treatment of depression in HIV-infected patients
92. Fluoxetine treatment of major depression in patients with AIDS
93. Poststroke depression and fluoxetine
94. Depression in the elderly physically ill: A open study of treatment with the 5-HT reuptake inhibitor fluoxetine
95. Comparative tolerability profiles of the newer versus older antidepressants
96. The side effect profile and safety of fluoxetine
97. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine
98. Drug safety monitoring of 12 692 patients treated with fluoxetine
99. Adverse events and treatment discontinuations in fluoxetine clinical trials
100. Fluoxetine-induced mania in a patient with post-stroke depression
101. A new case of fluoxetine-induced mania in poststroke depression
102. Changes in adverse events reported by patients during 6 months of fluoxetine therapy
103. Fluoxetine therapy in patients with obesity and insulin-dependent diabetes mellitus
104. Fluoxetine in elderly patients: Is there cause for concern?
105. The fluoxetine and suicide controversy: A review of the evidence
106. Serotonin syndrome: Incidence, symptoms and treatment
107. Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertaline
108. Retrospective review of selective serotonin reuptake inhibitor-induced libido disturbance in women
109. Female sexual side effects associated with selective serotonin reuptake inhibitors: A descriptive clinical study of 33 patients
110. Sexual dysfunctioning in users of selective serotonin reuptake inhibitors (SSRIs)
111. Antidepressant-induced sexual dysfunction: A multicenter and prospective study using a questionnaire of 693 patients
112. The role of serotonin in sexual dysfunction: Fluoxetine associated orgasm dysfunction
113. Changes in weight during a 1-year trial of fluoxetine
114. Fluoxetine in depressed geriatric patients: Effect on weight
115. Antidepressants and weight: A comparative study of four antidepressants and their effect on the weight of depressed patients
116. Fluoxetine versus sertraline and paroxetine in major depression: Long-term changes in weight
117. Weight gain during fluoxetine treatment
118. Paradoxical effects of fluoxetine [letter]
119. A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies
120. Fluoxetine and suicide: A meta-analysis of controlled trials of treatment for depression
121. Prospective study of fluoxetine treatment and suicidal behavior in affectively ill subjects
122. Systematic review and guide to selective serotonin reuptake inhibitors
123. Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients
124. The efficacy of imipramine in the treatment of HIV-related depression
125. Effects of imipramine on mood and enumerative measures of immune status in depressed patients with HIV illness
126. Treating depression in HIV-positive patients
127. Psychopharmacotherapy of psychiatric syndromes in asymptomatic and symptomatic HIV infection
128. Effects of nortriptyline on depression and glycemic control in diabetes: Results of a double blind, placebo-controlled trial
129. Treating depression in diabetic patients
130. Diabetes mellitus and major depressive disorder: An overview of prevalence, complications, and treatment
131. Amitriptyline and weight gain: A biochemical and endocrinological study
132. Weight gain: A side effect of tricyclic antidepressants
133. Amitriptyline, weight gain and carbohydrate cravings: A side effect
134. Changes occurring in appetite and weight during short-term antidepressant treatment
135. Antidepressant therapy in the physically ill: A therapeutic opportunity for the selective 5-HT re-uptake inhibitors?
136. Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs
137. Treatment issues in poststroke depression
138. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy
139. Pros and cons of fluoxetine for the depressed cancer patient
140. Psychiatric emergencies in terminally ill cancer patients
141. Group psychotherapy for HIV-seropositive patients with major depression
142. Fluoxetine: A pharmacoeconomic review of its use in depression
143. Antidepressants and suicide
144. Which antidepressant? A commentary from general practice on evidence based medicine and health economics
145. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism
146. Recent pharmacologic advances in antidepressant therapy for the elderly
147. Fluvoxamine: An updated review of its use in the management of adults with anxiety disorders
148. Are pharmacokinetic drug interactions with SSRIs an issue?
149. The clinician and drug interactions - An update
150. Protease inhibitors for the treatment of human immunodeficiency virus infection
151. Guidelines for the use of antiretroviral agents in HIV-infected adults and adoloscents: Table XIV. Drug interactions between antiretrovirals and other drugs
152. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents: Table XIII. Drugs that should not be used with antiretrovirals
153. Update: Clinically significant cytochrome P-450 drug interactions